Clinical Trials Logo

Pleura Mesothelioma clinical trials

View clinical trials related to Pleura Mesothelioma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04115111 Completed - Pleura Mesothelioma Clinical Trials

Diadem to Investigate the Activity and Safety of Durvalumab

Diadem
Start date: October 17, 2018
Phase: Phase 2
Study type: Interventional

Malignant pleural mesothelioma (MPM) is a cancer with high mortality rate and few therapeutic options.essentially all patients usually progress and die subsequently to a first line therapyl. There is strong evidence that the immune system is deeply involved in the biogenesis of MPM and that an imbalance in pro-inflammatory cytokines and exhausted adaptive T-cell mediated immune response are the main causes of neoangiogenesis, progression and metastatisation processes.Numerous Phase II-III clinical trials are underway evaluating Durvalumab either as monotherapy or combination with evidence of activity in a wide range of solid tumors. Durvalumab has received FDA approval as second line treatment in patients with locally advanced or metastatic urothelial carcinoma. Given these prospects for PD-L1 Ab, a Phase II study is proposed in order to evaluate the activity and safety of Durvalumab in advanced pretreated MPM.